SCHEMBL5337350

SCHEMBL5337350

COc1ccc(Oc2ccccc2)cc1Nc1ncnc2ccsc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 7/20 0.52
RIPK2 O43353 1/20 0.52
EPHB2 P29323 1/20 0.52
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
MAPT P10636 2/20 0.47
KDM4E B2RXH2 1/20 0.47
CSNK2A1 P68400 1/20 0.46
MAPK1 P28482 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
FADS1 O60427 1/20 0.45
HTT P42858 2/20 0.44
GAA P10253 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PDE4A P27815 1/20 0.44
PDE4B Q07343 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5317160 0.88 MEN1 (0.55) EGFRMEN1KMT2AALDH1A1HPGD
SCHEMBL5313425 0.83 HTT (0.56) EGFRALDH1A1HPGDMAPTKDM4E
SCHEMBL5317272 0.81 HTT (0.54) EGFRMEN1KMT2AFADS1HTT
SCHEMBL7890118 0.81 TEK (0.63) EGFRRIPK2EPHB2SMN1; SMN2FADS1
SCHEMBL5314819 0.80 FADS1 (0.58) EGFREPHB2MAPK1FADS1
SCHEMBL5463906 0.80 EGFR (0.49) EGFRMEN1KMT2AFADS1HTT
SCHEMBL5333554 0.80 KMT2A (0.67) EGFRMEN1KMT2AALDH1A1HPGD
Hydrochloric Acid SCHEMBL7890132 0.80 TEK (0.61) EGFRRIPK2EPHB2KMT2AMAPT
Hydrochloric Acid SCHEMBL5473031 0.79 MEN1 (0.65) EGFRMEN1KMT2AALDH1A1HPGD
SCHEMBL5331005 0.79 CSNK2A1 (0.58) EGFRHPGDMAPTCSNK2A1FADS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007056215-A9 N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF CYTOVIA INC (US) 2007-09-13 WO claimed
WO-2007056215-A2 N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF CYTOVIA, INC. (US) 2007-05-18 WO claimed
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-05-03 US claimed
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP4, CASP3, API5 EGFR 1226/4885RIPK2 1556/4885EPHB2 3318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.